Skip to main content

Table 2 Critical appraisal

From: Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review

Reference Design Relevance Validity
Dom Det Out Blind Rec SoC Loss Mis
Outcome: MTX efficacy         
[16] Retrospective (validation prospective) + + +/− + + + + +
[17] Mixed retrospective and prospective + + +/− + + + + +
[18] Prospective + + +/− + + + + ?
[19] Prospective + + +/− +/− + ? ? +
[20] Cross-sectional + + +/− +/− + ? ? +
[10] Retrospective + + +/− ? + ? + +
[21] Retrospective + + +/− ? + ? ? +
[22] Mixed retrospective and prospective + +/− +/− ? + ? + +
[23] Prospective (validation unknown) + +/− +/− ? + ? ? ?
[24] Prospective (validation unknown) + +/− +/− ? + ? ? ?
[25]a Retrospective +/− +/− + ? + ? +/− +
[26] Prospective +/− + +/− ? + ? + +
[27] Prospective +/− + +/− ? + ? + +/−
[28] Prospective +/− + +/− ? + ? + ?
[29] Retrospective +/− +/− + ? + ? +/− +
[25]b Retrospective +/− +/− +/− ? + ? +/− +
[30] Retrospective + + - ? + ? + +
[31] Cross-sectional + + - +/− + ? ? ?
[32] Retrospective + +/− - +/− + ? ? ?
[33] Retrospective +/− + - ? + ? ? +
Outcome: MTX adverse effects        
[34] Prospective + + +/− + + + + +
[18] Prospective + + +/− + + + ? ?
[10] Retrospective + + +/− ? + ? + +
[21] Retrospective + + +/− ? + ? ? +
[20] Cross-sectional + + +/− +/− + ? ? +
[31] Cross-sectional + + +/− +/− + ? ? ?
[32] Retrospective + +/− +/− +/− + ? ? ?
[35] Cross-sectional - + + ? - ? + +
  1. Abbreviations: Blind blinding, Det determinant, Dom domain, Loss loss to follow up, Mis missing predictors, Ou t outcome, Rec recruitment, SoC standardization of care.
  2. Bold articles were excluded for analysis.
  3. aPredictors after 6 months for outcome after 5 years; bPredictors at baseline for outcome after 6 months.
  4. Criteria: Domain: + Children with confirmed JIA, according to currently valid ILAR criteria, starting MTX +/− Children with JCA/JRA according to previously valid criteria, or children with JIA and additional criteria (e.g. hospitalized, specific categories only), starting MTX - Children without JIA/JCA/JRA, or no MTX; Determinant: + Prediction model or single predictors corrected for confounding in multivariable analysis +/− Single predictors in univariate analysis - No predictors; Outcome: + Efficacy: Any standardized outcome measurement, follow up >1 year. Adverse effects: Any outcome measurement, follow up >1 year +/− follow-up <1 year - Efficacy: No use of standardized outcome criteria; Blinding: + Both patient and physician blinded (or not applicable in case of objective measurements) +/− Patient or physician not blinded - Not blinded; Recruitment: + Predictors determined at time of start of MTX or <6 months (or time of determination does not matter as in genetic evaluations, gender, age at onset, etc.) +/− Predictors determined more than 6 months after start of MTX, but <1 year - Predictors determined after 1 year, or completely at random; Standardization of care: + All participants treated according to standards of care - No standardized care; Loss to follow up (missing outcome): + <20% and unselective loss to follow up; or >20%, unselective and solved with a statistically valid method (imputation) +/− >20% (not imputed) but unselective loss to follow up - Selective loss to follow up; Missing predictors: + <20% and unselective; or >20%, unselective and solved with a statistically valid method (imputation) +/− >20% (not imputed) but unselective - Selective missing predictors.